CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
PLAINSBORO, N.J., Aug. 17, 2017 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will present at the Wells Fargo Healthcare Conference and the Morgan Stanley Healthcare Conference in September.
- On Thursday, September 7, 2017 at 10:00 a.m. ET, Glenn Coleman, chief financial officer and corporate vice president of International, will present at the Wells Fargo Healthcare Conference in Boston, MA. A live audio webcast of the presentation can be accessed at Integra’s Investor Relations website at http://investor.integralife.com/.
- On Tuesday, September 12, 2017 at 2:05 p.m. ET, Peter Arduini, president and chief executive officer, will present at the Morgan Stanley Healthcare Conference in New York City. A live audio webcast of the presentation can be accessed at Integra’s Investor Relations website at http://investor.integralife.com/.
About Integra
Integra LifeSciences (NASDAQ:IART) is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: Integra LifeSciences Holdings Corporation Investor Relations: Michael Beaulieu Director, Investor Relations (609) 750-2827 [email protected]
